IFNG and melanoma: In patients with stage III melanoma receiving neoadjuvant therapy, baseline intratumoral IFNγ scores also predict responses, with 95% of patients with IFNγ-high tumours achieving a pathological response, compared to 59% in patients with IFNγ-low tumours [11].